Spots Global Cancer Trial Database for Examine Maximum Tolerated Dose and Pharmacokinetic and Pharmacodynamic Profile
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Examine Maximum Tolerated Dose and Pharmacokinetic and Pharmacodynamic Profile
Official Title: Phase I Study of CG200745 to Examine the Maximum Tolerate Dose, Pharmacokinetic and Pharmacodynamic Profiles, and Safety Among Patients With Progressive Solid Cancer
Study ID: NCT01226407
Conditions
Interventions
Study Description
Brief Summary: Open label, single dose and phase I study. The primary objective: To determine the maximum tolerated dose in Single dose The secondary objective: to evaluate the toxicity in administration to determine desirable dosing amount for phase II to evaluate tumor response in progressive solid cancer patients to evaluate pharmacokinetic/ pharmacodynamic profile.
Detailed Description: 1. Number of Subjects: 28\~36, dose escalation (2\~6 subject of each step) 2. Adverse Events will be coded to preferred therm and body system using the CTCAE
Keywords
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Seoul Asan Medical Center, Seoul, , Korea, Republic of
Contact Details
Name: Tae Won Kim, MD, PhD
Affiliation: Seoul Asan medical Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
